The NEOLAP Trial: Unlocking the Potential of GDF-15 as a Biomarker in Pancreatic Cancer
The Challenge: Poor Outcomes in Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) is a formidable cancer with grim long-term outcomes, even for patients with localized disease. The NEOLAP trial aimed to tackle this challenge by exploring a novel strategy: induction chemotherapy followed by surgery. The goal was to increase the chances of a margin-negative (R0) resection, which is crucial for survival.
The NEOLAP Trial: A Biomarker-Driven Approach
The NEOLAP trial (AIO-PAK-0113) was a phase II study conducted in a multicenter, randomized setting. It enrolled patients with therapy-naïve, locally advanced (borderline resectable or unresectable), non-metastatic PDAC. These patients received 4 months of induction chemotherapy with either nab-paclitaxel plus gemcitabine or FOLFIRINOX. The trial's unique strength was its focus on biomarker evaluation, specifically the role of growth differentiation factor-15 (GDF-15).
GDF-15: A Stress-Induced Immune Regulator
GDF-15, also known as macrophage inhibitory cytokine-1, is a fascinating molecule. Under normal physiological conditions, it is barely expressed. However, when cells face stress, such as inflammation, tissue injury, metabolic imbalance, or even cancer, GDF-15 production is triggered. In cancer, elevated GDF-15 levels have been linked to poor outcomes, including PDAC. Importantly, GDF-15 doesn't directly reflect tumor size; instead, it acts as a stress-induced, immune-regulatory mediator, influencing interactions between tumor cells, the tumor environment, and the body's systemic response.
Methods and Findings
The study measured GDF-15 levels in the blood (circulating GDF-15 or cGDF-15) at the start of the trial and after 4 months of chemotherapy. It also analyzed tumor tissue (tumor GDF-15 or tGDF-15) before and after treatment. The results were striking:
- Prognostic Power: Low baseline cGDF-15 levels were strongly associated with longer overall survival, with patients living an average of 21.9 months compared to 12.7 months for those with higher cGDF-15. This effect held true even for patients who didn't undergo R0 resection.
- Predictive Potential: Low baseline cGDF-15 also predicted a higher likelihood of achieving R0 resection, with a significant increase in success rates (36.5% vs. 13.9%).
- Chemotherapy Impact: Circulating GDF-15 levels rose significantly during chemotherapy, especially with platinum-based regimens. However, these changes didn't correlate with treatment response, resection status, or CA 19-9 levels.
- Tumor Expression: While tGDF-15 expression was rare at baseline, it increased significantly after chemotherapy, mirroring the rise in cGDF-15. Higher baseline cGDF-15 levels were linked to detectable tGDF-15, and the conversion from negative to positive tGDF-15 after chemotherapy strongly correlated with increasing cGDF-15 levels.
Conclusion: GDF-15 as a Biomarker
The NEOLAP trial highlights GDF-15 as a powerful biomarker in localized, non-metastatic PDAC. Low baseline cGDF-15 identifies patients with improved survival and a higher chance of successful surgery. The consistent induction of GDF-15 during chemotherapy, especially with platinum-based regimens, suggests a biologically relevant role in treatment response and disease progression. These findings open up exciting possibilities for future PDAC clinical trials focused on GDF-15-directed strategies.
Explore More:
Read the full article here: ESMO Gastrointestinal Oncology Article
